Oxford researchers reported Wednesday that Shingrix, the newer recombinant shingles vaccine, is associated with a lower risk of heart disease, extending a research line from the same team that linked the vaccine to reduced dementia risk two months ago. [1] The study, published in Nature Medicine, is built around a "natural experiment": researchers compared roughly 72,000 people aged 60 and older who were vaccinated in the six months just before or just after Shingrix displaced the older live vaccine, Zostavax, in the United States in October 2017. [1]

That design exists specifically to answer a confound that has dogged earlier observational work on the vaccine — whether people who choose to get vaccinated are simply healthier, or have better health-care access, than people who don't. By comparing two groups vaccinated on either side of a single approval date rather than vaccinated versus unvaccinated people generally, the Oxford team tried to isolate the vaccine itself as the variable. [1] The result: over seven years of follow-up, people who received Shingrix instead of Zostavax showed a 9% lower overall cardiovascular burden — a composite of coronary heart disease, heart failure, and stroke. Coronary heart disease specifically was reduced by 10% and heart failure by 12%; strokes fell 12% in men but not significantly in women, and atrial fibrillation was 7% lower across the group. In absolute terms, those relative-risk figures translate to roughly 1% fewer cardiovascular events after seven years. [1]

Mark Russell, a rheumatologist at King's College London who was not involved in the study, put the population-level stakes in context: "Although the benefits are relatively small on an individual basis, millions of people receive shingles vaccination, meaning that even a small cardiovascular benefit could translate into a substantial number of cardiovascular events prevented at a population level." [1] Study co-author Maxime Taquet of Oxford went further, telling reporters that "if confirmed, Shingrix could prevent hundreds of thousands of cardiovascular events in the USA alone, and may be the first vaccine that protects the heart and the brain." [1]

That "heart and brain" line is doing most of the work in how the finding is spreading. STAT's own social post distilled the study into exactly that framing — "first vaccine protecting both heart and brain" — and the phrase has traveled well beyond the caveats STAT's own article carries. Buried in the same piece that produced the viral quote is Taquet's own qualification: "This study remains observational, even though it's a natural experiment, and so we are keen to see results from randomized controlled trials. And one of them is underway." [1] That trial, DAN ZOSTER, is following roughly 162,000 people in Denmark, with first results expected in 2027 — meaning the randomized confirmation Taquet himself says is needed will not arrive for at least another year. [1]

The mechanism remains speculative even to the study's own authors. Fabiana Corsi-Zuelli, an Oxford psychiatry researcher and co-author, suggested the recombinant vaccine "may induce trained immunity" — durable changes in immune-system cells — while cardiovascular medicine researcher Betty Raman proposed that resulting cytokine activity could reduce the inflammation that drives atherosclerosis. Taquet pointed specifically to AS01, an adjuvant present in Shingrix but absent from Zostavax, noting that "we haven't seen any protection of Zostavax vaccines for cardiovascular disease, and the natural experiments have not found any effect on cardiovascular outcome" — a comparison that at least narrows where the effect might originate, without confirming it. [1] Kaleen Hayes, a pharmacoepidemiologist at Brown University who was not involved in the research, called the cardiovascular question "really the next question everyone was wondering about" after the earlier dementia finding, while noting the evidence on cardioprotective effects remains "conflicting." [1]

None of that uncertainty is a reason to dismiss the finding — a natural-experiment design specifically built to rule out confounding is stronger evidence than a simple vaccinated-versus-unvaccinated comparison, and the researchers behind it are the same team whose dementia-risk work already reshaped how clinicians talk about the vaccine. It is a reason to notice that the version of this story racing across social media has already dropped the word "observational" that its own authors keep repeating.

The practical stakes are real regardless of how the randomized trial turns out. Shingles vaccination rates among older adults remain well below public-health targets in most countries, and Taquet said directly that he hopes the cardiovascular finding, layered on top of the dementia result, will "nudge" more eligible adults to get the shot — while insisting the primary reason to vaccinate remains preventing shingles itself, not the possible secondary benefits still awaiting confirmation. That is a more modest claim than "protects the heart and the brain," and it is the one buried furthest from the headline.

-- NORA WHITFIELD, Chicago